{
    "id": 25764,
    "fullName": "ESR1 over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "ESR1 over exp indicates an over expression of the Esr1 protein and/or mRNA. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 2099,
        "geneSymbol": "ESR1",
        "terms": [
            "ESR1",
            "ER",
            "Era",
            "ESR",
            "ESRA",
            "ESTRR",
            "NR3A1"
        ]
    },
    "variant": "over exp",
    "createDate": "11/28/2016",
    "updateDate": "04/15/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 16448,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Ibrance (palbociclib) and H3B-5942 demonstrated synergy in an ESR1 (ER alpha)-positive breast cancer cell line overexpressing wild-type ESR1, resulting in decreased proliferation in culture (PMID: 29991605).",
            "molecularProfile": {
                "id": 26888,
                "profileName": "ESR1 over exp"
            },
            "therapy": {
                "id": 8022,
                "therapyName": "H3B-5942 + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14484,
                    "pubMedId": 29991605,
                    "title": "Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ER\u03b1WT and ER\u03b1MUT Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29991605"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9544,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a patient-derived xenograft (PDX) model of breast cancer with over expression of ESR1 demonstrated resistance to treatment with Falsodex (fulvestrant), replicating the resistance seen in the patient (PMID: 27765850).",
            "molecularProfile": {
                "id": 26888,
                "profileName": "ESR1 over exp"
            },
            "therapy": {
                "id": 744,
                "therapyName": "Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 7266,
                    "pubMedId": 27765850,
                    "title": "Reactivation of p53 by MDM2 Inhibitor MI-77301 for the Treatment of Endocrine-Resistant Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27765850"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16446,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, H3B-5942 inhibited ESR1 (ER alpha) target gene expression and proliferation of ESR1-positive breast cancer cell lines overexpressing wild-type ESR1 in culture, and inhibited tumor growth in xenograft models (PMID: 29991605).",
            "molecularProfile": {
                "id": 26888,
                "profileName": "ESR1 over exp"
            },
            "therapy": {
                "id": 8021,
                "therapyName": "H3B-5942",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14484,
                    "pubMedId": 29991605,
                    "title": "Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ER\u03b1WT and ER\u03b1MUT Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29991605"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16447,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Verzenio (abemaciclib) and H3B-5942 demonstrated synergy in an ESR1 (ER alpha)-positive breast cancer cell line overexpressing wild-type ESR1, resulting in decreased proliferation in culture (PMID: 29991605).",
            "molecularProfile": {
                "id": 26888,
                "profileName": "ESR1 over exp"
            },
            "therapy": {
                "id": 8028,
                "therapyName": "Abemaciclib + H3B-5942",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14484,
                    "pubMedId": 29991605,
                    "title": "Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ER\u03b1WT and ER\u03b1MUT Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29991605"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9546,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Falsodex (fulvestrant) and SAR405838 (MI-77301) inhibited tumor growth in an endocrine-resistant patient-derived xenograft (PDX) model of breast cancer with high ESR1-over expression and wild-type TP53, but did not demonstrate increased efficacy over SAR405838 (MI-77301) alone (PMID: 27765850).",
            "molecularProfile": {
                "id": 26889,
                "profileName": "ESR1 over exp TP53 wild-type"
            },
            "therapy": {
                "id": 5068,
                "therapyName": "Fulvestrant + SAR405838",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 7266,
                    "pubMedId": 27765850,
                    "title": "Reactivation of p53 by MDM2 Inhibitor MI-77301 for the Treatment of Endocrine-Resistant Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27765850"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9547,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SAR405838 (MI-77301) inhibited tumor growth in an endocrine-resistant patient-derived xenograft (PDX) model of breast cancer with high ESR1-over expression and wild-type TP53 (PMID: 27765850).",
            "molecularProfile": {
                "id": 26889,
                "profileName": "ESR1 over exp TP53 wild-type"
            },
            "therapy": {
                "id": 2078,
                "therapyName": "SAR405838",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7266,
                    "pubMedId": 27765850,
                    "title": "Reactivation of p53 by MDM2 Inhibitor MI-77301 for the Treatment of Endocrine-Resistant Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27765850"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 26843,
            "profileName": "ESR1 over exp MAPK1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26888,
            "profileName": "ESR1 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26889,
            "profileName": "ESR1 over exp TP53 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}